ENTA News and Press, Enanta Pharmaceuticals Inc. From 01/04/24

Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024 Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhib...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 42 nd Annu...

2023-12-05 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-30 15:34:48 ET Summary Two mid-stage studies RSVHR and RSVPEDs are being advanced using EDP-938 for RSV; data from at least one of these studies expected Q3 of 2024. Data to be released from phase 2a challenge study, using L-protein inhibitor EDP-323, expected in Q3 of 202...

2023-11-22 16:50:36 ET More on Enanta Pharma Historical earnings data for Enanta Pharma Financial information for Enanta Pharma For further details see: Enanta Pharmaceuticals files for a $150M mixed shelf offering

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is one of today's top gainers. The company's shares have moved 5.51% on the day to $8.81. Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its...

2023-11-21 09:59:42 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...

2023-11-20 21:43:05 ET Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Conference Call November 20, 2023, 04:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Off...

2023-11-20 16:02:57 ET More on Enanta Pharma Enanta Pharma Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Enanta Pharma Historical earnings data for Enanta Pharma Financial information for Enanta Pharma For further details see: En...